Navigation Links
John Theurer Cancer Center and LLS host panel discussion with leading hematologists
Date:6/9/2010

Hackensack, N.J., June 9, 2010The John Theurer Cancer Center at Hackensack University Medical Center and The Leukemia & Lymphoma Society (LLS) have come together to host Partners in Progress: An Expert Panel Discussion on Advancing Therapies for Blood Cancers on Tuesday, June 22 in Hackensack, NJ. This free educational program is for patients, caregivers, and healthcare providers. It will feature leading leukemia experts, as well as a myelodysplastic syndrome (MDS) survivor and clinical trial participant.

"Thanks to medical advancements, many people with hematological malignancies have the opportunity to live long, productive lives," said Louis DeGennaro, Ph.D., LLS's executive vice president and chief mission officer. "We are excited to partner with the John Theurer Cancer Center to bring much-needed education to patients, their loved ones, and the healthcare providers that support them."

Blood cancers include leukemia, lymphoma, and myeloma and account for nearly ten percent of new cancer cases diagnosed each year. An estimated 53,000 Americans will die from blood cancers this year, accounting for nearly ten percent of deaths from cancer.

"The John Theurer Cancer Center is pleased to partner with The Leukemia & Lymphoma Society to offer this important education program to oncology professionals, and additional support to our patients." said Andrew Pecora, M.D., F.A.C.P., C.P.E., chairman and executive administrative director, the John Theurer Cancer Center.

Topics to be discussed at this program include: describing the decision making process; explaining ways to help patients become active participants in their care; defining informed consent for treatment in a clinical trial; and describing financial health challenges facing patients with blood cancers.

Featured Speakers:

  • Louis J. Degennaro, Ph.D.Executive Vice President and Chief Mission Officer, The Leukemia & Lymphoma Society
  • Stuart L. Goldberg, M.D.Chief, Division of Leukemia, the John Theurer Cancer Center at Hackensack University Medical Center and Associate Clinical Professor of Medicine, University of Medicine & Dentistry of New Jersey
  • Gail J. Roboz, M.D., Director, Leukemia Program, Associate Professor of Medicine, Weill Medical College of Cornell University
  • Maria Baldo, M.S., PA-CSenior Physician Assistant, Leukemia Service, Weill Medical College of Cornell University
  • John J. HughesMDS Survivor and Clinical Trial Participant

"Educational discussions such as this are critical to helping patients with blood cancers manage these diseases effectively," said Stuart Goldberg, M.D., chief, Division of Leukemia, the John Theurer Cancer Center. "I am thrilled to join this group of world-class professionals to discuss the latest advancements in blood cancers."

This education program is for patients and caregivers of blood cancers, as well as oncology nurses and social workers involved in the treatment of this class of cancers. It is supported by an educational grant from Genentech and Biogen Idec, and an educational donation from Amgen. Registration is complimentary and 2.0 continuing education contact hours are available for both nurses and social workers.


'/>"/>

Contact: Amy Leahing
amy.leahing@widmeyer.com
646-213-7245
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. The John Theurer Cancer Center recognizes medical physics team for safety track record
2. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
3. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
4. John Theurer Cancer Center offers breakthrough radiation measurement technology
5. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
6. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
7. Compound enhances cancer-killing properties of agent in trials
8. Cadmium investigated as cause of endometrial cancer
9. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
10. VARI findings could help diagnose and treat liver cancer
11. Intervention program helps breast cancer patients live longer after recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... and laboratory-grade deionized water from the same place. From 101 Water Texas, here ... Satisfaction: Patients and staff can enjoy a continuous supply of pure, fresh, oxygenated ...
(Date:4/23/2017)... CA (PRWEB) , ... April 23, 2017 , ... ... solutions and managed services announced the achievement of Cisco Select certification and SMB ... throughout the United States. , In earning the Select Certification, Altura ...
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/22/2017)... PA (PRWEB) , ... April 22, 2017 , ... ... experience to his role as Vice President of Sales and Business Development at ... key GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: